Non Hodgkin Lymphoma (NHL) Global Market Report 2024

The non hodgkin lymphoma (nhl) market has grown strongly in recent years. It will grow from $9.34 billion in 2023 to $10.23 billion in 2024 at a compound annual growth rate (CAGR) of 9.4%. Historical growth in the management of non-Hodgkin lymphoma (NHL) can be credited to several factors. These include the increased incidence of NHL cases, advancements in diagnostic tools, developments in chemotherapy and immunotherapy treatments, ongoing clinical research and drug development efforts, as well as improvements in survival rates for individuals diagnosed with NHL.

The non hodgkin lymphoma (nhl) market is expected to see strong growth in the next few years. It will grow to $14.13 billion in 2028 at a compound annual growth rate (CAGR) of 8.4%. The projected expansion during the forecasted period can be ascribed to the increasing elderly demographic, advancements in targeted therapies and immunotherapy, precision medicine developments, heightened awareness leading to early detection. Key trends anticipated in this period encompass the surge in biosimilars, incorporation of next-generation sequencing, uptake of CAR-T cell therapies, introduction of new chemotherapy agents, as well as the utilization of real-world evidence and outcomes research.

The anticipated surge in the non-Hodgkin lymphoma market is primarily fueled by the condition's widespread prevalence. Non-Hodgkin lymphoma, a cancer originating in the lymphatic system, is becoming increasingly common among populations. As highlighted by the American Cancer Society's January 2023 report, it constitutes 4% of all cancers and is projected to affect approximately 80,550 Americans in 2023, leading to an estimated 20,180 fatalities. Similarly, data from the Canadian Cancer Society in May 2022 indicated 11,400 diagnosed cases of non-Hodgkin lymphoma in Canada that year, resulting in 3,000 fatalities. This escalating prevalence underscores the driving force behind the non-Hodgkin lymphoma market's growth.

The burgeoning elderly population is poised to be a key driver for the expansion of the non-Hodgkin lymphoma (NHL) market. With a higher incidence of this ailment among older adults, the specialized care and treatment required for this segment emphasize the market's trajectory. As forecasted by the World Health Organization in October 2022, the global elderly population, defined as individuals aged 65 and above, is set to reach 2.1 billion by 2050, making up one-sixth of the world's populace by 2030. Consequently, the rising demographic of elderly individuals contributes significantly to the expansion of the non-Hodgkin lymphoma (NHL) market.

The non-Hodgkin lymphoma market is witnessing a significant trend in drug innovation, driving advancements in treatment options. Companies operating in this sector are actively pursuing product innovation to fortify their market positions. Genentech Inc.'s December 2022 FDA approval for Lunsumio, a novel bispecific antibody targeting relapsed or refractory follicular lymphoma, exemplifies this trend. This immunotherapy, a fixed-duration cancer treatment, provides readily available options for patients without delays in receiving treatment, based on positive outcomes from Phase II GO29781 research.

Major players in the non-Hodgkin lymphoma market are intensifying their focus on introducing cutting-edge immunotherapies such as Epcoritamab-bysp (EPKINLY) to gain a competitive edge. This investigational subcutaneous immunotherapy, targeting CD20-expressing B-cell malignancies, has exhibited promising results in clinical trials, notably in relapsed or refractory B-cell non-Hodgkin lymphoma. AbbVie Inc.'s November 2023 breakthrough therapy designation from the FDA for Epcoritamab-bysp (EPKINLY) in treating adult patients with relapsed or refractory follicular lymphoma marks a significant milestone. Additionally, the EMA's validation of a Type II application for epcoritamab (TEPKINLY) for the same indication is supported by encouraging results from the Phase 1/2 EPCORE NHL-1 clinical trial, involving 128 adult patients with relapsed or refractory CD20+ mature B-cell non-Hodgkin's lymphoma (NHL), including FL.

In August 2022, AstraZeneca plc, a prominent UK-based pharmaceutical and biotechnology entity, completed the undisclosed acquisition of TeneoTwo Inc. This strategic move aims to significantly enhance and diversify AstraZeneca's product lineup by incorporating oncology medications and a pipeline featuring TNB-486, a phase I clinical-stage CD19/CD3 T-cell engager specifically tailored for addressing relapsed and refractory B-cell non-Hodgkin lymphoma. TeneoTwo Inc., based in the US, specializes in biotechnological advancements within oncology, notably in the realm of treatments for NHL.

Major companies operating in the non hodgkin lymphoma (nhl) market report are Bayer AG, Teva Pharmaceutical Industries Ltd., F. Hoffmann La Roche Ltd., Merck & Co. Inc., Eli Lilly and Co., Novartis AG, GlaxoSmithKline plc, AbbVie Inc., AstraZeneca plc, Takeda Pharmaceutical Company Limited, Bristol Myers Squibb Co., Pfizer Inc., Celgene Corporation, Sanofi S.A., Janssen Pharmaceuticals Inc., Johnson & Johnson, Biogen Idec, Boehringer Ingelheim GmbH, Eisai Co. Ltd., Gilead Sciences, Incyte Corporation, Karyopharm Therapeutics, Kite Pharma Inc., Kyowa Hakko Kirin Co. Ltd., MorphoSys AG, Nordic Nanovector ASA, Ono Pharmaceutical Co. Ltd., Seattle Genetics Inc., Spectrum Pharmaceuticals Inc.

North America was the largest region in the non-Hodgkin lymphoma (NHL) market in 2023. Asia-Pacific is expected to be the fastest-growing region in the global non-Hodgkin lymphoma (NHL) market report during the forecast period. The regions covered in the non hodgkin lymphoma (nhl) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the non hodgkin lymphoma (nhl) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The main types of NHL include B-cell lymphoma and T-cell lymphoma. B-cell lymphoma involves abnormal B lymphocytes in the immune system. Treatment for B-cell lymphomas often encompasses a combination of therapies such as chemotherapy, immunotherapy, targeted therapy, radiation therapy, and potentially stem cell transplants. Various treatment modalities including surgery, stem cell transplants, chemotherapy, immunotherapy, targeted therapy, and radiation therapy can be administered through different routes such as oral or parenteral methods. These treatments are available through diverse distribution channels including hospital pharmacies, retail outlets, online pharmacies, and others. They are utilized by various end-users including hospitals, homecare facilities, specialty centers, and other medical settings.

The non Hodgkin lymphoma market research report provides non Hodgkin lymphoma market statistics, including non Hodgkin lymphoma industry global market size, regional shares, competitors with a non Hodgkin lymphoma market share, detailed non Hodgkin lymphoma market segments, market trends and opportunities, and any further data you may need to thrive in the non Hodgkin lymphoma industry. This non Hodgkin lymphoma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The non-Hodgkin lymphoma market includes revenues earned by entities by treating aggressive lymphomas, indolent lymphomas, Burkitt lymphoma, lymphoma and leukemia, and B-cell lymphomas. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.